NANETS2022 15th Annual Multidisciplinary NET Medical Symposium NANETS 2022 Other (12 abstracts)
An Appraisal of Findings from a Neuroendocrine Neoplasm (NEN) Tumor Board (TB): Is There Added Value or Is It Redundant?
Nikolaos A Trikalinos 1 , Chet Hammill 2 , Jingxia Liu 3 , Pooja Navale 4 , Kyle Winter 1 , Deyali Chatterjee 5 , Amir Iravani 6 , Manik Amin 7 & Malak Itani 8
1Department of Medicine, Division of Oncology, Washington University Medical School, St. Louis, MO, USA and Siteman Cancer Center, St Louis, MO, USA; 2Department of Surgery, Washington University in St. Louis, St Louis, MO, USA; 3Division of Public Health Sciences, Washington University Medical School, St. Louis, MO, USA; 4Department of Pathology and Immunology, Washington University School of Medicine, St. Louis MO; 5Department of Pathology, University of Texas MD Anderson Cancer Center, Houston, TX, USA; 6Department of Radiology, Fred Hutchinson Cancer Center, University of Washington, Seattle, WA; 7Department of Medical Oncology, Dartmouth Hitchcock Medical Center, NH, 03766, USA; 8Mallinckrodt Institute of Radiology, Washington University School of Medicine, St. Louis, MO.
Background: Subspecialty tumor boards (TB) are uncommon and their benefit has not been clearly demonstrated for patients and providers alike. We tried to determine the decision patterns of a newly minted neuroendocrine neoplasm (NEN) tumor board (TB) and the factors behind those.
Methods: We retrospectively reviewed all NEN TB recommendations from 07/2018 to 12/2021 and recorded patient characteristics, TB outcomes and associations between them.
Results: A total of 652 patient entries were identified. Median age of participants was 61 years and an equal number of men and women were presented. Most patients (33.4%) had tumors originating in the small bowel with 16.8% of high grade and 25.9% of pancreatic origin. Imaging was reviewed 97.2% of the time, with most frequently reviewed modalities being PET (55.3%) and CT (44.3%). Imaging review determined that there was no disease progression 20.8% of the time and significant treatment changes were recommended in 36.1% of patients. Major pathology amendments occurred in 3.7% of cases and a clinical trial was identified in 2.6%. There was no association between patient or disease presentation with the tumor board outcomes. There was a slight decrease in number of patients discussed per session, from 10.0 to 8.2 (P<0.001) when the TB transitioned to a virtual format during the COVID-19 pandemic but all other factors remained unchanged.
Conclusion: NEN TB relies heavily on image review, can impact significant treatment changes in patients with rare tumors like NENs, and was not affected by the switch to a virtual format. Finally, none of the examined factors were predictive of the tumor board recommendations.
Conclusion: NEN TB relies heavily on image review, can impact significant treatment changes in patients with rare tumors like NENs, and was not affected by the switch to a virtual format. Finally, none of the examined factors were predictive of the tumor board recommendations.
Abstract ID 21582
Volume 89
Article tools
My recent searches
My recently viewed abstracts
Authors
Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2024 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more